Furthermore, in advanced HFrEF, GLP-1 RA is not recommended due to the increased risk of serious cardiac adverse events, and initiating sulfonylureas is not recommended in adults with T2D and recent hHF due to the possible increased risk of mortality and new hospitalization. This evidence concerns the gene GLP1R and type 2 diabetes mellitus.